Reviva Pharmaceuticals is at a pivotal junction, advancing its lead candidate brilaroxazine through critical Phase 3 schizophrenia trials backed by positive safety and efficacy data. Despite encouraging clinical milestones, the firm continues to face significant liquidity constraints and Nasdaq compliance hurdles that threaten its public listing and operational runway. Recent capital raises and a reverse stock split have extended its cash runway into early 2027, but the necessity for further funding remains a dominant risk factor. Monitoring regulatory interactions alongside financial discipline will be key for Reviva’s near-term trajectory.